Upndown, There are numerous ways that the deal/deals might be constructed. Since CX-717/ADHD will now be a hot property again for partnering, it could be partnered separately with a pharma that has a particular interest in ADHD. And with Servier now out of the picture and the global Neurodegenerative rights reassembled, that gives another area for partnering, with a BP that has a particular interest in AD/Parkinson's/Neurodegenerative diseases. That deal would also involve Cortex's high impacts, with the BP also providing Cortex with some ongoing R+D funding.
Other possibilities might include a single large BP wanting to partner the whole enchilada. Or Cortex might possibly want to partner global Neurodegenerative/high impacts in 2007, but keep CX-717/ADHD inhouse and then partner it after doing a larger ADHD Phase 2b. So there are many ways to do it. The combination of having CX-717 safely back in the mix, plus the global Neurodegenerative rights reassembled, provides a lot of favorable partnering scenarios for Cortex.
Then there is the non-Ampakine in-licensing idea. As Neuro suggested, it might make sense to wait until the plans for these other deals are finalized before pulling the trigger on that one.
Market Data 
Markets 
AI
